Current Rheumatology Reports

, Volume 7, Issue 5, pp 407–415 | Cite as

Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis

  • Molly D. Magnano
  • Mark C. Genovese


Rheumatologists, in addition to providing subspecialty care, are frequently called to treat general medical conditions in their patients with rheumatoid arthritis (RA). Co-morbid medical problems are common in the RA population and may require a different approach from standard practice recommendations. In this paper, we review the evaluation and treatment of cardiovascular disease, chronic kidney disease, gastrointestinal disease, depression, and metabolic bone disease in patients with RA. Appreciation of the unique interaction between arthritis and common medical co-morbidities may have a significant impact on manage-ment and outcomes of RA.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Hochberg MC, Spector TD: Epidemiology of rheumatoid arthritis: update. Epidemiol Rev 1990, 12:247–52.PubMedGoogle Scholar
  2. 2.
    Katz JN, Barrett J, Liang MH, et al.: Utilization of rheumatol-ogy physician services by the elderly. Am J Med 1998, 105:312–318.PubMedCrossRefGoogle Scholar
  3. 3.
    Kirwan JR, Snow SM: Which patients see a rheumatologist? Br J Rheum 1991, 30:285–287.CrossRefGoogle Scholar
  4. 4.
    Palferman TG: Principles of rheumatoid arthritis control. J Rheumatol 2003, 67(Suppl):10–13.Google Scholar
  5. 5.
    Wolfe F, Mitchell DM, Sibley JT, et al.: The mortality of rheu-matoid arthritis. Arthritis Rheum 1994, 37:481–494.PubMedCrossRefGoogle Scholar
  6. 6.
    Doran MF, Pond GR, Crowson CS, et al.: Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002, 46:625–631.PubMedCrossRefGoogle Scholar
  7. 7.
    MacLean CH, Louie R, Leake B, et al.: Quality of care for patients with rheumatoid arthritis. JAMA 2000, 284:984–992. A large historic cohort study examining the quality of health care received by RA patients in general versus subspeciality practice. The authors examined process measures, rather than outcome measures, to determine quality scores for arthritis, co-morbid disease, and health care maintenance. This study concluded that overall quality of health care was suboptimal in the majority of patients studied.PubMedCrossRefGoogle Scholar
  8. 8.
    Rincon ID, Williams K, Stern MP, et al.: High incidence of cardiovascular events in a rheumatoid arthritis not explained by traditional cardiovascular risk factors. Arthritis Rheum 2001, 44:2737–2748. The first study of cardiovascular risk in RA that focused on fatal and nonfatal cardiovascular events. In this cohort analysis of the Outcome of Rheumatoid Arthritis Longitudinal Evaluation study group, the authors examined the incidence of cardiovascular events and the role of traditional cardiovascular risk factors in patients with RA compared with a control population.PubMedCrossRefGoogle Scholar
  9. 9.
    Solomon DH, Karlson EW, Rimm EB, et al.: Cardiovascular morbidity and mortality in women diagnosed with rheuma-toid arthritis. Circulation 2003, 107:1303–1307.PubMedCrossRefGoogle Scholar
  10. 10.
    Myllykangas-Luosujaarvi R, Aho K, Kautiainen H, et al.: Cardio-vascular mortality in women with rheumatoid arthritis. J Rheumatol 1995, 22:1065–1067.Google Scholar
  11. 11.
    Kitas GD, Erb N: Tackling ischemic heart disease in rheuma-toid arthritis. Rheumatology 2003, 42:607–613.PubMedCrossRefGoogle Scholar
  12. 12.
    Solomon DH, Curhan GC, Rimm EB, et al.: Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004, 50:3444–3449.PubMedCrossRefGoogle Scholar
  13. 13.
    Dessein PH, Stanwix AE, Joffe BI: Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002, 4:R5.PubMedCrossRefGoogle Scholar
  14. 14.
    Wilson PW, D’Agostino RB, Levy D: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837–1847.PubMedGoogle Scholar
  15. 15.
    Cisternas M, Gutierrez MA, Klaassen J, et al.: Cardiovascular risk factors in Chilean patients with rheumatoid arthritis. J Rheumatol 2002, 8:1619–1622.Google Scholar
  16. 16.
    Bacon PA, Stevens RJ, Carruthers DM, et al.: Accelerated athero-genesis in autoimmune rheumatic diseases. Autoimmun Rev 2002, 1:338–347.PubMedCrossRefGoogle Scholar
  17. 17.
    Wolfe F, Freundlich B, Straus WL: Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003, 30:36–40.PubMedGoogle Scholar
  18. 18.
    Danesh J, Collins R, Appleby P, et al.: Association of C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998, 279:1477–1482.PubMedCrossRefGoogle Scholar
  19. 19.
    Koenig W, Pepys M: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augburg study 1984 to 1992. Circula-tion 1999, 99:237–242.Google Scholar
  20. 20.
    Wolbink GJ, Brouwer MC, Buysmann S, et al.: CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C reactive protein complexes. J Immunol 1996, 157:473–79.PubMedGoogle Scholar
  21. 21.
    U.S. Preventive Services Task Force (USPSTF): Guide to clinical preventive services, 3rd ed, 2000–2002. clinic/uspstfix.htm; Accessed date January 21, 2005.Google Scholar
  22. 22.
    Smith SC, Blair SN, Bonow RO, et al.: AHA/ACC Guidelines for preventing heart attact and death in patients with athero-sclerotic cardiovascular disease: 2001 update. Circulation 2001, 104:1577–1579.PubMedGoogle Scholar
  23. 23.
    McCarey DW, McInnes IB, Madhok R, et al.: Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004, 363:2015–2021.PubMedCrossRefGoogle Scholar
  24. 24.
    Icardi A, Araghi P, Ciabattoni M, et al.: Kidney involvement in rheumatoid arthritis. Reumatismo 2003, 55:76–85.PubMedGoogle Scholar
  25. 25.
    Cobb S, Anderson F, Baurer W: Length of life and causes of death in rheumatoid arthritis. N Eng J Med 1953, 249:553–556.CrossRefGoogle Scholar
  26. 26.
    Laakso M, Mutru O, Isomaki H, et al.: Mortality from amyloido-sis and renal diseases in patients with rheumatoid arthritis. Ann Rheum Dis 1986, 45:663–667.PubMedCrossRefGoogle Scholar
  27. 27.
    Sihvonen S, Korpela M, Mustonen J, et al.: Renal disease as a predictor of increased mortality among patients with rheum-atoid arthritis. Nephron Clin Pract 2004, 96:107–114.CrossRefGoogle Scholar
  28. 28.
    National Kidney Foundation: K/DOQI clinical practice guide-lines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002, 39:S1.CrossRefGoogle Scholar
  29. 29.
    Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999, 106:13S-24S.PubMedCrossRefGoogle Scholar
  30. 30.
    Gambaro G, Perazella MA: Adverse renal effects of anti-inflam-matory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 2003, 253:643–652.PubMedCrossRefGoogle Scholar
  31. 31.
    Schiff MH, Whelton A: Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2000, 30:196–208. A thorough review of the renal toxicity of DMARDs currently used for the treatment of RA. This article is current, comprehensive, and offers pragmatic recommendations for dosing and monitoring DMARDs in the setting of renal insufficiency.PubMedCrossRefGoogle Scholar
  32. 32.
    Cush JJ, Tugwell P, Weinblatt M, et al.: US consensus guide-lines for the use of cyclosporine A in rheumatoid arthritis. J Rheumatol 1999, 26:1176–1186.PubMedGoogle Scholar
  33. 33.
    Hall CL, Fothergill NJ, Blackwell MM, et al.: The natural course of gold nephropathy: a long-term study of 21 patients. Br Med J 1987, 295:745–748.CrossRefGoogle Scholar
  34. 34.
    Rodriguez G, Jick H: Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994, 343:769–772.CrossRefGoogle Scholar
  35. 35.
    Silverstein FE, Graham DY, Senior JR, et al.: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. A randomized, double-blind placebo-controlled trial. Ann Intern Med 1995, 123:241–249.PubMedGoogle Scholar
  36. 36.
    Walsh JH, Peterson WL: The treatment of helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995, 333:984–989.PubMedCrossRefGoogle Scholar
  37. 37.
    Voutilainen M, Sokka T, Juhola M, et al.: Nonsteroidal anti-inflammatory drug associated upper gastrointestinal lesions in rheumatoid arthritis patients. Scand J Gastroenterol 1998, 33:811–816.PubMedCrossRefGoogle Scholar
  38. 38.
    Schallross TM, Rathone BJ, Wyatt JI, et al.: Helicobacter pylori associated chronic gastritis and peptic ulceration in patients taking nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther 1990, 4:551–522.Google Scholar
  39. 39.
    Loeb DS, Talley NJ, Ahlquist DA, et al.: Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori. Gastroenterology 1992, 102:1899–1905.PubMedGoogle Scholar
  40. 40.
    Chan FK, To KF, Wu JC, et al.: Eradication of helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002, 359:9–13.PubMedCrossRefGoogle Scholar
  41. 41.
    Hunt RH, Bazzoli F: Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment Pharmacol Ther 2004, 19(Suppl:1):9–16.PubMedCrossRefGoogle Scholar
  42. 42.
    Chan FKL, Graham DY: Review article: prevention of non-steroidal anti-inflammatory drug gastrointestintal complica-tions — review and recommendations based on risk assessment. Aliment Pharmacol Ther 2004, 19:1051–1061.PubMedCrossRefGoogle Scholar
  43. 43.
    Richy F, Bruyere O, Ethgen O, et al.: Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 2004, 63:759–766.PubMedCrossRefGoogle Scholar
  44. 44.
    Chan FK, Hung LC, Suen BY, et al.: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002, 347:2104–2110.PubMedCrossRefGoogle Scholar
  45. 45.
    Garcia Rodriguez LA, Jick H: Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994, 343:769–772.CrossRefGoogle Scholar
  46. 46.
    Stoltz CM, Baime MJ, Yaffe K: Depression in the patient with rheumatologic disease. Rheum Dis Clin North Am 1999, 25:687–702.PubMedCrossRefGoogle Scholar
  47. 47.
    Dickens C, McGowan L, Clark-Carter D, et al.: Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med 2002, 64:52–60.PubMedGoogle Scholar
  48. 48.
    Frank RG, Beck NC, Parker JC, et al.: Depression in rheuma-toid arthritis. J Rheumatol 1988, 15:920–925.PubMedGoogle Scholar
  49. 49.
    Blalock SJ, DeVellis RF, Brown GK, et al.: Validity of the Center for Epidemiological Studies Depression Scale in arthritis populations. Arthritis Rheum 1989, 32:991–997.PubMedCrossRefGoogle Scholar
  50. 50.
    Katz PP, Yelin EH: Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis. J Rheu-matol 1993, 20:790–796.Google Scholar
  51. 51.
    Abdel-Nasser AM, Abd El-Azim S, Taal E, et al.: Depression and depressive symptoms in rheumatoid arthritis patients: an analysis of their occurrence and determinants. Br J Rheumatol 1998, 37:391–397.PubMedCrossRefGoogle Scholar
  52. 52.
    Whooley MA, Simon GE: Managing depression in medical outpatients. N Engl J Med 2000, 26:1942–1950.CrossRefGoogle Scholar
  53. 53.
    Mulrow CD, Williams JW, Gerety MB, et al.: Case-finding instruments for depression in primary care settings. Ann Intern Med 1995, 122:913–921.PubMedGoogle Scholar
  54. 54.
    Martens MP, Parker JC, Smarr KL, et al.: Assessment of depres-sion in rheumatoid arthritis: a modified version of the center for epidemiologic studies depression scale. Arthritis Rheum 2003, 49:549–555.PubMedCrossRefGoogle Scholar
  55. 55.
    Whooley MA, Avins AL, Miranda J, et al.: Case-finding instru-ments for depression: two questions are as good as many. J Gen Intern Med 1997, 12:439–445.PubMedCrossRefGoogle Scholar
  56. 56.
    Haugeberg G, Uhlig T, Falch JA, et al.: Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: Results from 394 patients in the Oslo County rheumatoid arthritis. Arthritis Rheum 2000, 43:522–530.PubMedCrossRefGoogle Scholar
  57. 57.
    Huusko TM, Korpela M, Karppi P, et al.: Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland. Ann Rheum Dis 2001, 60:521–522.PubMedCrossRefGoogle Scholar
  58. 58.
    Shibuya K, Hagino H, Morio Y: Cross-sectional and longitudinal study of osteoporosis in patients with rheumatoid arthritis. Clin Rheumatol 2002, 21:150–158.PubMedCrossRefGoogle Scholar
  59. 59.
    Michel BA, Bloch DA, Fries JF: Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991, 18:804–808.PubMedGoogle Scholar
  60. 60.
    Gabriel SE, Tosteson AN, Leibson CL, et al.: Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 2002, 13:323–330.PubMedCrossRefGoogle Scholar
  61. 61.
    Melton LJ: Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 2003, 18:1139–1141.PubMedCrossRefGoogle Scholar
  62. 62.
    Bromley M, Woolley DE: Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 1984, 27:968–975.PubMedCrossRefGoogle Scholar
  63. 63.
    Goldring SR: Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheum 2002, 14:406–410.CrossRefGoogle Scholar
  64. 64.
    Marshall D, Johnell O, Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312:1254–1259.PubMedGoogle Scholar
  65. 65.
    Peel NF, Moore DJ, Barrington NA, et al.: Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995, 54:801–806.PubMedGoogle Scholar
  66. 66.
    Haugeberg G, Orstavik RE, Kvien T: Effects of rheumatoid arthritis on bone. Curr Opin Rheum 2003, 15:469–475. A compact review of the effect of RA and drugs used to treat RA on bone density and integrity. Examines the biologic mechanisms for local and systemic osteoporosis and the rationale for therapies targeting mediators of inflammation and bone cell destruction.CrossRefGoogle Scholar
  67. 67.
    Njeh CF, Genant HK: Bone loss: quantitative imaging techniques for assessing bone mass in rheumatoid arthritis. Arthritis Res 2000, 2:446–450.PubMedCrossRefGoogle Scholar
  68. 68.
    Diez-Perez A, Marin F, Vila J, et al.: Evaluation of calcaneal quantitative ultrasound in a primary care setting as a screening tool for osteoporosis in postmenopausal women. J Clin Densitom 2003, 6:237–245.PubMedCrossRefGoogle Scholar
  69. 69.
    Greenspan SL, Rosen HN, Parker RA: Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 2000, 85:3537–3540.PubMedCrossRefGoogle Scholar
  70. 70.
    Feskanich D, Willett W, Colditz G: Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA 2002, 288:2300–2306.PubMedCrossRefGoogle Scholar
  71. 71.
    Greenspan SL, Resnick NM, Parker RA: Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003, 289:2525–2533.PubMedCrossRefGoogle Scholar
  72. 72.
    Body JJ, Gaich GA, Scheele WH, et al.: A randomized doubleblind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87:4528–4535.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Molly D. Magnano
    • 1
  • Mark C. Genovese
  1. 1.Division of Immunology and RheumatologyStanford University School of MedicinePalo AltoUSA

Personalised recommendations